The number of cellular and gene therapy-based oncology treatments being developed has grown exponentially over the past ten years. Towards continuing momentum, the Society for Immunotherapy of Cancer (SITC) hosted the Cellular Therapy Regulatory Summit to define hurdles causing delays in development and regulatory review of these important products, as well as provide actionable solutions. The results of this summit are detailed in this newly released executive summary.
